SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript
May 13, 2026
Earnings Call Speaker Segments
Thanks, Tawanda. Good afternoon, and I appreciate everyone being on the SeaStar Medical First Quarter 2026 Financial Results Conference Call. This is Jackie Cossmon, and I'm with Wheelhouse Life Science Advisors. With me today from SeaStar Medical are Eric Schlorff, our Chief Executive Officer; Dr. Kevin Chung, our Chief Medical Officer; Tim Varacek, Senior Vice President of Commercial and Business Operations; and Mike Messinger, our Chief Financial Officer. I want to remind those listening that remarks management makes on this call will contain forward-looking statements as defined under federal securities laws. Such forward-looking statements carry risks and uncertainties and and might lead actual results to differ materially from any results that are anticipated. To see a list and description of those risks and uncertainties, please look at SeaStar Medical's filings with the Securities and Exchange Commission. In addition, what's presented on the conference call is information accurate only as of the date of the live broadcast, May 13, 2026. Except where the law requires it, SeaStar Medical assumes no obligation to revise or update any statements to reflect events or circumstances; and now I'd like to turn the call over to Eric. Eric?
Thanks. I appreciate it, Jackie, and I want to welcome everyone who's on the line with us today. We're moving along nicely when it comes to hitting the targets we set for 2026, and we're staying careful about how we spend our money. A larger group of QUELIMMUNE customers has driven our QUELIMMUNE net revenue for the first quarter, which rose by almost 70% compared with the first quarter of 2025, and 7 new hospitals brought QUELIMMUNE therapy on board during the first quarter of 2026. We're aiming for 15 new customers this year, and we're making solid headway toward that figure; as our footprint grows and QUELIMMUNE keeps getting adopted in the pediatric AKI market, we feel we're positioned to reach our net revenue target of roughly $2 million for the year. Even more significant, we're laying the groundwork for what could be a much bigger opportunity ahead of us in the adult AKI market. Along those lines, we're still enrolling patients in the neutralized AKI pivotal trial, and 198 patients have signed up out of the 339 patients we plan to enroll in total. During the prior year, we made the decision to bring on additional clinical sites so we could broaden our enrollment push and wrap up enrollment near the close of 2026. Kevin and his group are putting in hard work to get that done. It's been deeply gratifying to watch top-tier medical institutions take part in our trial, with UCLA serving as one illustration of 1 of the most recent hospitals to come aboard, and others are on the way; beyond that, we remain in close collaboration with the FDA on multiple matters. To start, we're talking through what would go into a modular PMA submission for the adult AKI indication, which we think might accelerate the approval timeline. Next, we're engaging with the FDA to secure agreement on rapid approval pathways for our SCD therapy. The SCD therapy could potentially save lives in indications where no treatments exist right now, and we feel that patients dealing with hyperinflammation ought to get faster access to therapies capable of reducing or preventing serious organ damage and possible death. Last, and before I hand things over to Tim, we've kept up solid financial discipline. Mike will walk you through what we've been doing on that side in a moment. So now I'll pass the call to Tim, who will cover not just what we've accomplished commercially but also how we're establishing a robust presence within the pediatric AKI community.
Thank you, Eric, and I appreciate all of you being with us today. It's a pleasure to share that we closed out the first quarter with considerable momentum, and that momentum is carrying over into this year's second quarter. As Eric pointed out, we brought on 7 more customers during the first quarter, and what's significant is that we're observing a rise in orders across many of our customers. Net revenue for QUELIMMUNE during the first quarter came to $495,000, which represents a healthy 69% gain versus the first quarter of last year. As Eric mentioned, this market, while small, matters a great deal to us — not just because we think QUELIMMUNE is preserving lives and protecting organ function in young children, but also because it offers strong confirmation of our SCD technology and, crucially, it opens the door to potential future opportunities within the adult market. The pediatric health care community is showing tremendous excitement about QUELIMMUNE therapy. Just recently, for instance, we sponsored and hosted an educational symposium at the AKI and CRRT meeting in San Diego. Our participation at that meeting, along with several other initiatives, is intended to boost awareness, knowledge and implementation of QUELIMMUNE therapy so we can keep strengthening our brand in pediatric AKI and also establish SeaStar Medical in a leadership position to help inform the pediatric medical community about this significant unmet need. That symposium gave the pediatric community a chance to obtain answers on critical operational questions, be exposed to abundant content drawn from cutting-edge scientific and clinical data, and apply those learnings to set up QUELIMMUNE therapy at the hospitals where they practice. The growing influence of QUELIMMUNE therapy, together with the pediatric health care community's appetite to understand more about QUELIMMUNE, underscores a central priority for SeaStar Medical: to intensify educational efforts around QUELIMMUNE therapy and the way it should be implemented when treating pediatric AKI. Now let me address our commercial push for QUELIMMUNE in 2026. We hold high hopes for helping patients by getting QUELIMMUNE therapy into additional pediatric hospitals. We remain focused on bringing on new sites as fast as we can; and after a site takes up QUELIMMUNE, making sure of pull-through by educating the patient care teams, so their attention stays on pediatric AKI and on the possibility of QUELIMMUNE therapy for suitable patients; we feel this is merely the start of the commercial possibilities for our SCD therapy. With that, I'll hand the presentation over to Kevin Chung, our Chief Medical Officer. Kevin?
Thank you, Tim, and I appreciate all of you joining this call. Tim's excitement regarding our showing at the AKI and CRT meeting in late March is something I share. Speaking as someone who practices critical care medicine, what stood out to me was how thoroughly QUELIMMUNE has worked its way into the discussion. It wasn't just our own sessions or data presentations drawing attention. The presence surfaced naturally during plenary and breakout sessions, with clinicians and researchers bringing up QUELIMMUNE without being prompted; that sort of grassroots visibility within a specialty community carries real meaning. On top of that momentum, the American Society of Nephrology's kidney news, broadly considered the newsroom of the nephrology field, gave over not 1 but 2 articles to the SCD therapy in its latest issue. The first, a feature covering how tricorporial therapy has evolved, named the SCD therapy as among the most exciting frontiers in the move away from passive blood filtration toward active immune modulation. The second focused completely on the SED therapy, covering its mechanism, clinical evidence and future potential. When the publication of the leading nephrology Society grants a therapy like this this level of editorial attention, it signals meaningfully that the SCD therapy is moving into mainstream clinical consciousness. We really appreciate being acknowledged by conferences and publications, but the acknowledgment that carries the greatest weight happens with patients receiving care. Every month, we run a virtual call for clinical users, connecting with pediatric nephrology and critical care teams—both those already using our product and those considering it—across the country, so we can review each QUELIMMUNE case as a group. The stories shared on these calls are truly extraordinary, and they continually confirm and strengthen our conviction about how important it is to make this therapy available to more patients. Our FCD's unique way of modulating the immune system could let us reshape how serious conditions are treated — not only AKI, but also cardio renal syndrome, cardiac surgery, end-stage renal disease, and other situations where pathological immune activation occurs, with uncontrolled cytokine release causing organ failure and death. Given that, we're pushing to complete enrollment in the pivotal neutralize AKI study. As a brief recap, neutralize AKI is a randomized controlled trial designed to test whether as many as 10 consecutive SCD treatments, each lasting 24 hours, can boost 90-day survival or renal recovery in critically ill adults who have acute kidney injury and need continuous renal replacement therapy. The main goal we're measuring is a combined outcome of death or needing dialysis by the 90-day mark. We continue adding new clinical sites, and enrollment now stands at 198 out of the 339 patients we're targeting. Our plan is to finish signing up patients near the end of the year, which should let us potentially share top line findings sometime in mid-2027. Talks are already underway with the FDA about our strategy for a modular PMA submission, which would let us get most of the filing done aside from the pivotal data, with that pivotal data coming in as the final piece. The idea behind this approach is to give the FDA a chance to look at modules early on that aren't tied to the clinical trial data. Often, that speeds up the overall review of those submissions. Once the neutralized AKI clinical trial is finished and assessed, and provided efficacy and safety results come back favorable, our plan is to act swiftly and file the rest of the PMA components under the breakthrough device designation we hold, which puts us in position for a possibly faster FDA review. Should a PMA approval come through for SCD therapy in adult AKI, we could commercialize it as a therapeutic device, free of the IRB-linked obstacles that come with QUELIMMUNE. Hospital uptake would become considerably easier, and our belief is that this will fuel quicker commercial growth; I'll now discuss our SAVE Registry, which follows commercial usage of QUELIMMUNE among critically ill children. In March, we shared that enrollment had closed at 50 patients, which is a significant milestone. At present — right now we are wrapping up the 28-day safety analysis for the last patients enrolled and anticipate sending top line safety data to the FDA before long. Together with that filing, we will make a formal ask that the SAVE Registry shift from the mandatory status it holds now into a voluntary post-marketing study. Should the FDA consent, that would cut the administrative load on children's hospitals in a substantial way, speeding adoption and widening access to QUELIMMUNE at additional pediatric centers, plainly a win for patients, providers, and the health care system. Having said that, I'll pass things to our CFO, Mike Messinger. Mike?
Thanks, Kevin. It means a lot to be involved in this, and I appreciate everyone joining our call today. I'll give you a quick rundown of how we did financially in the first quarter of 2026. Just so you know, our Form 10-Q is going to be submitted to the SEC sometime in the next 24 hours, and it will contain a more detailed review of the company's results for the 3 months that ended March 31, 2026. That 10-Q will be available at sec.gov or on our site, seastartmedical.com. Net revenue from QUELIMMUNE sales came in at roughly $495,000 during the first quarter of 2026, which compares with $293,000 in the first quarter of 2025; and, as Tim noted, adoption of QUELIMMUNE continues to look strong in the second quarter of 2026. Now on to gross profit. Our first quarter statement of operations shows a gross profit margin above 90%, which matches what we saw in the prior 3 quarters. Keep in mind, we did not recognize cost of goods sold during the first quarter of 2025, because the QUELIMMUNE units that were sold had initially been expensed to research and development before approval and commercialization, in line with U.S. GAAP. Operating expenses stayed flat at roughly $4.1 million in the first quarter of 2026 versus the first quarter of 2025. That reflects the discipline we've maintained and how we leverage our team's capacity to handle several responsibilities across the organization, thanks to our wide-ranging experience, talent and enthusiasm for making sure the company succeeds; for the rest of the year, we expect to hit our enrollment targets. We anticipate research and development expenses rising modestly, by about 5% per quarter, as we keep pushing enrollment and back additional clinical sites. That said, we still expect general and administrative spending to stay fairly steady from one quarter to the next through the rest of 2026. Net loss for the first quarter of 2026 came to roughly $3.5 million, or $0.90 per share, using weighted average shares outstanding of about 3.9 million shares; that's against a net loss of roughly $3.8 million, or $4.38 per share, in the first quarter of 2025, which used about 862,000 weighted average shares outstanding. As of March 31, 2026, we hold more than $9.3 million in cash on our balance sheet, up from $5.2 million at March 31, 2025. Now I'll hand things back to Eric.
Thanks, Mike. What we wanted to accomplish on this call was to walk you through what we've achieved lately, and at the same time make clear just how tightly we're concentrating on the value drivers that matter most to those we serve, especially patients, the medical community and investors. We have a team that's small yet deeply committed, and we think we're changing what's possible for children who, absent new therapies capable of modulating the cytokine storm in AKI, all too often confront organ failure or death. Beyond that, by uniting the pediatric care community so that understanding of critical care in this setting grows broader, we think we're contributing to a higher standard of care for every child dealing with the trauma of acute kidney injury; on top of that, through participation in our neutralized AKI pivotal trial, we've built relationships with numerous leading nephrologists across the country. Those ties will benefit us as we contemplate a potential launch of our SCD therapy in the adult indication. And last, we're working hard with our stakeholders to keep communicating the value proposition and long-term vision we have for SeaStar Medical. In our view, the opportunities SeaStar has in front of it are substantial, and we're eager to report on our progress going forward; having said that, I'll turn it over to the operator so we can take questions. Operator.
Thanks for the update today. So my first question: have repeat orders started coming in from any of those pediatric centers already in place, and if so, how soon after they first get up and running are those reorders showing up?
David, Eric here. Appreciate you being on the call. That's a good one. Tim, would you like to field it?
Absolutely, glad to address that. Regarding your first point, we certainly do observe customers ordering again. As for how quickly that occurs, it truly depends on how the patient presents when they come in; sometimes there may be a gap between patients; other times, once therapy wraps up for one patient, additional suitable QUELIMMUNE candidates will show up in the ICU. So in that sense it's quite hard to predict, yet it's certainly fair to say that across the broader customer base, after using the product, they build familiarity with it. Repeat orders are definitely something we have.
All right, excellent. And then you brought up earlier the SAVE Registry and, naturally, how encouraging every bit of the data coming out of it is; so when do you address whether that is going to have an impact on treatment guidelines or, say, standard of care discussions?
Yes. That is an excellent question. So Kevin, would you like to take that one?
Right. So getting something into the standard of care and written into guidelines is a lengthy process. That said, there's the pediatric ATK consensus document that came out just over 12 months ago. It does reference immune modulation — extracorporeal immune modulation gets a mention there. So my view is that if we keep going the way we are and we get a positive neutralize AKI study, then the pediatric PK and that consensus statement are going to move SCD forward as a recommended therapy. Now, with these clinical practice guidelines, usually you need several randomized controlled trials plus broad adoption before recommendations actually show up; but we're in there already, which is encouraging; and I'm certain that as the therapy keeps being used and clinical teams witness the results, this will turn into something everyone's discussing.
All right, that's great. And finally, obviously, you brought up those pieces in the ASN Kidney news. Something they brought up in that coverage was that folding the SCD into the IC workflow is — I believe their word was nontrivial — but what I'm asking is, just how nontrivial is it, or how simple is it, for that unit to get worked into a hospital's protocols?
Yes, I appreciate you asking that. Kevin, go ahead.
Yeah. Thanks for asking that. From a clinical standpoint, then, you're adding the SCD cartridge and linking it in series with a CRT circuit that's already running. A dialysis technician, an NCR technician, or a CRT ICU nurse is able to handle that. Hooking it up requires just minutes. Nothing could be more straightforward — plus, plenty of centers nationwide already know their way around citrate anticoagulation. We're lucky that's true, since it plays an essential role in what we do; so as far as whether it's hard, if a citrate protocol is already in place and you're accustomed to performing CRT, as is the situation in 99% of all ICUs across the country — that statement is accurate: getting SCD up and running won't be tough.
Okay, so I’d like to focus on the hospitals where the product is being used right now. Is there a specific ordering pattern — anything — any additional detail you can share? I realize you mentioned reorder frequency and that you don’t have that precise figure, but how many patients in total have received treatment? And at present, do you have something like a reordering trend for those hospitals and average revenue per center? Or does it truly depend on the patient and vary a lot?
Thank you, Anthony. That’s an excellent question. I appreciate you being with us today. I’ll address part of it, and then I’ll ask Tim to join in as well. One point is the number of patients we’ve treated — a few months ago we shared that we had hit 50 patients for the SAVE Registry. That should give you a rough idea of how many have been treated. Perhaps you could add a bit more detail on some of Anthony’s remaining questions?
Certainly. Here's how I'd frame it, Anthony — and I appreciate you raising it — because this applies to a lot of the products we sell into hospitals. Once a hospital gets a clear picture of how it's using something, it establishes a par value, which is essentially the stock level it wants to have available at all times, determined by that usage. And keep in mind, par values are already in place with a number of our existing customers, while with others we're still building out the business, correct? At present we have 17 customers — a year ago at this point, I honestly don't recall, but we had 3 or 4. So it remains early days, and a lot of these newer accounts place an order, they put the product to use, and then they observe the pattern of patients coming through the system, which is what allows them to settle on a par value. Beyond that, the more they work with it, the more pediatric AKI comes to mind, and you've heard me describe the education work we're deeply involved in across many of these sites, to ensure QUELIMMUNE creates a genuine ripple effect throughout those institutions, so that plenty of people are aware of it. And they are proactively seeking out patients. And when you proactively seek out patients, you'll typically identify a greater number of them. So that's essentially the way it functions. We don't break things out by revenue per hospital right now. This indication and condition is ultra-rare. So it's really the arrival of a patient within the hospital system itself that drives it.
All right. So when you're trying to boost how many patients come in, and as you mentioned, it really hinges on patients who require the treatment. That said, is there any extra education happening at the hospitals you already work with, plus the new ones you're attempting to bring on board, that might speed up uptake at additional centers?
Good question. In fact, no, that's fine. I would actually — Kevin, perhaps you could speak to the monthly users call that we hold, and on those calls what gets talked about, and so forth.
Absolutely, and thanks for asking that, Anthony. The pediatric nephrology and critical care field is really a close-knit group — everyone knows everyone and communicates regularly. They exchange their experiences, and we try to build on that culture by holding monthly clinical users calls, which we mentioned in the update. When we send out invitations, roughly 135 or 50 people are invited, and typically around 60 participants join by phone. During these calls, they hear about cases from the prior months that took place at each of the participating sites. We get into the specifics of those cases — how ill the patients were, the reasoning and justification behind choosing the therapy, and what the outcomes were. Obviously, we can't rescue everyone, but for a large number of these patients — in fact, for every one of them — they're beginning SCD in an extremely critical circumstance, when the patient is profoundly unwell. Nearly all of them, in my view, would not have survived without this treatment option. What we're providing is an opportunity, and these cases get talked about where — the patient is 66, they begin QUELIMMUNE — and before long, the inflammatory markers begin to decline, and they describe patients who are doing well. So when people at institutions that don't yet have QUELIMMUNE hear these accounts, naturally they want to obtain it, because they want to give their kids a chance. That's essentially how we get the word out about what QUELIMMUNE might be able to do. On top of that, we've given presentations at essentially all the leading conferences where pediatric intensivists and nephrologists come together. PNRC, the pediatric research network Consortium — we presented there in Miami, with around 50 children's hospitals represented. Society Critical Care Medicine, ACT — and even the European meeting I just came back from had multiple pediatric centers from the United States in attendance. The discussion always revolves around how positively these patients respond to QUELIMMUNE at the outset. Even in a case where someone dies, they observe the inflammatory markers dropping and the patients improving initially. At times, due to underlying conditions, they may not make it, yet they still witness the benefit. So honestly, I'd characterize it as word of mouth on steroids, and it works quite well. Many centers reach out to us, sometimes before they've even started the process, because they have a trial that requires it, and we help however we can.
That sounds good. And Tim, perhaps you could also give a bit of an overview of this newly created team — the advanced practice group you've assembled?
Absolutely, Eric, glad to take that one. Alongside the points Kevin raised, we're approaching community education through several different avenues. One step we took was establishing an advanced provider practice provider ad board. These individuals operate right at the bedside level — highly operational people who handle much of the actual work inside these institutions, building out various orders and protocols and running training. In numerous cases, they serve as the champions inside their institutions, guiding QUELIMMUNE across that hospital system. So we're collaborating with them. We held a symposium at the latest AKI and CRRT meeting. Several additional events are scheduled for the remainder of this year. Beyond that, we've also placed some field level clinical support at these systems — particularly those that have brought QUELIMMUNE on board — to ensure, once again, that awareness spreads: plenty of staff work inside any given hospital. Shift changes happen frequently. As a result, many individuals still need exposure to this information. So I believe we've got a solid grasp of what must be done, and at this point we're carrying it out.
I appreciate it, Towanda, and I want to thank everyone for being with us on this call today as we go over SeaStar Medical's financial results for the first quarter. Should you have any questions, feel free to reach out to us at ir@cstarmed.com, or you can visit our website, www.starmedical.com. Thanks so much, and take care.
Everyone, that brings us to the end of today's call. We appreciate you joining us. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.